AnaptysBio (ANAB) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AnaptysBio (ANAB) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 129.2% versus a gain of 52.5%. Over five years, ANAB leads with a +138.8% price change compared with +24.8% for TYRA. AnaptysBio is the larger company by market cap ($1.35 billion vs $1.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | TYRA |
|---|---|---|
| Share price | $45.31 | $19.68 |
| Market cap | $1.35B | $1.35B |
| 1-day change | -0.74% | -3.51% |
| YTD return | +41.24% | -22.44% |
| 1-year return | +129.24% | +52.51% |
| 5-year return | +138.84% | +24.79% |
| Forward P/E | 8.94 | — |
| EPS (TTM) | $-0.96 | $-2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $40.65 |
| 52-week low | $20.18 | $13.29 |
| Distance from 52-week high | -37.38% | -51.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.56% | +141.17% |
| Average volume | 563.32K | 857.13K |
| Shares outstanding | 29.90M | 68.76M |
| Employees | — | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed TYRA by 76.7 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ANAB vs TYRA FAQ
Which is bigger, AnaptysBio or Tyra Biosciences?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.35B compared with $1.35B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, ANAB or TYRA?
ANAB returned +129.24% over the past 12 months, compared with +52.51% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.